ATR inhibitor · small molecule
berzosertib
0 active trials, targeting ATR. Not approved for any biomarker on marked.bio yet.
Also known as M6620, VX-970.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| BRCA1/2 mutation | 0 | 2 | – |
Trials
0 of 2 trials shown
-
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
berzosertibsacituzumab govitecan
Presence of pathogenic or likely pathogenic germline mutation/variant in BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, R…
BRCA1/2 mutationHRD Cancer, SCLC, Advanced Solid Tumors
-
M6620 (VX-970) in Selected Solid Tumors
Germline mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicte…
BRCA1/2 mutationSolid Tumor, Leiomyosarcoma, Osteosarcoma
No trials match these filters.